RS56153B1 - Varijante anti-cd40 antitela sa utišanim fc - Google Patents

Varijante anti-cd40 antitela sa utišanim fc

Info

Publication number
RS56153B1
RS56153B1 RS20170651A RSP20170651A RS56153B1 RS 56153 B1 RS56153 B1 RS 56153B1 RS 20170651 A RS20170651 A RS 20170651A RS P20170651 A RSP20170651 A RS P20170651A RS 56153 B1 RS56153 B1 RS 56153B1
Authority
RS
Serbia
Prior art keywords
silent
antibodies
variants
Prior art date
Application number
RS20170651A
Other languages
English (en)
Inventor
Christoph Heusser
James Rush
Karen Vincent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56153(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS56153B1 publication Critical patent/RS56153B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
RS20170651A 2010-11-15 2011-11-14 Varijante anti-cd40 antitela sa utišanim fc RS56153B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15
PCT/EP2011/070058 WO2012065950A1 (en) 2010-11-15 2011-11-14 Silent fc variants of anti-cd40 antibodies
EP11781571.2A EP2640749B1 (en) 2010-11-15 2011-11-14 Silent fc variants of anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
RS56153B1 true RS56153B1 (sr) 2017-11-30

Family

ID=44925566

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20170651A RS56153B1 (sr) 2010-11-15 2011-11-14 Varijante anti-cd40 antitela sa utišanim fc
RS20220319A RS63094B1 (sr) 2010-11-15 2011-11-14 Varijante anti-cd40 antitela sa utišanim fc

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20220319A RS63094B1 (sr) 2010-11-15 2011-11-14 Varijante anti-cd40 antitela sa utišanim fc

Country Status (38)

Country Link
US (8) US8828396B2 (sr)
EP (4) EP3502138B9 (sr)
JP (1) JP5782132B2 (sr)
KR (1) KR101632775B1 (sr)
CN (2) CN103209996B (sr)
AR (2) AR083847A1 (sr)
AU (1) AU2011331288B2 (sr)
BR (1) BR112013011644B1 (sr)
CA (1) CA2815921C (sr)
CL (1) CL2013001124A1 (sr)
CO (1) CO6801629A2 (sr)
CR (1) CR20130222A (sr)
CU (1) CU24057B1 (sr)
CY (1) CY1119097T1 (sr)
DK (2) DK2640749T3 (sr)
EA (1) EA026133B1 (sr)
ES (2) ES2633817T3 (sr)
GT (1) GT201300128A (sr)
HR (2) HRP20220413T1 (sr)
HU (2) HUE058015T2 (sr)
IL (1) IL225719A (sr)
JO (1) JO3266B1 (sr)
LT (2) LT3502138T (sr)
MA (1) MA34654B1 (sr)
MX (1) MX336633B (sr)
MY (1) MY159316A (sr)
NZ (1) NZ609549A (sr)
PE (1) PE20140979A1 (sr)
PL (2) PL3502138T3 (sr)
PT (2) PT3502138T (sr)
RS (2) RS56153B1 (sr)
SG (1) SG189928A1 (sr)
SI (2) SI2640749T1 (sr)
TW (2) TWI531581B (sr)
UA (1) UA112417C2 (sr)
UY (2) UY39292A (sr)
WO (1) WO2012065950A1 (sr)
ZA (1) ZA201302532B (sr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032025T2 (en) 2008-01-31 2017-08-28 Inserm - Inst Nat De La Sante Et De La Rech Medicale Antibodies to human CD39 and their use to inhibit regulatory T cell activity
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
JP5458188B2 (ja) * 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
CA2852056C (en) 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
KR101905346B1 (ko) 2011-04-21 2018-10-05 브리스톨-마이어스 스큅 컴퍼니 Cd40을 길항하는 항체 폴리펩티드
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
PT2766395T (pt) 2011-10-13 2020-02-04 Domantis Ltd Polipéptidos de anticorpo que antagonizam cd40l
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
DK2914627T3 (da) 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
EA035253B1 (ru) 2013-03-15 2020-05-21 Новартис Аг Лекарственные конъюгаты антител
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
AU2015302959B2 (en) 2014-08-12 2018-09-20 Novartis Ag Anti-CDH6 antibody drug conjugates
SG11201701341UA (en) 2014-10-10 2017-03-30 Innate Pharma Cd73 blockade
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
EP4047022A1 (en) 2015-05-29 2022-08-24 AbbVie Inc. Anti-cd40 antibodies and uses thereof
MX2018002708A (es) 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
CA2997263C (en) 2015-09-08 2022-10-04 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US10544229B2 (en) * 2015-09-30 2020-01-28 Janssen Biotech, Inc. Agonistic antibodies specifically binding CD40 and methods of use
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
US20190038628A1 (en) 2016-02-10 2019-02-07 Novartis Ag Use of inhibitors of the activity or function of pi3k for the treatment of primary sjogren's syndrome
JP7270379B2 (ja) 2016-03-08 2023-05-10 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ中和抗体
US20190071514A1 (en) 2016-03-14 2019-03-07 Innate Pharma Anti-cd39 antibodies
AU2017281830B2 (en) 2016-06-20 2023-04-06 Kymab Limited Anti-PD-L1 antibodies
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
WO2018083080A2 (en) 2016-11-04 2018-05-11 Innate Pharma Nkp46 ligand
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3574016A2 (en) 2017-01-24 2019-12-04 Innate Pharma NKp46 BINDING AGENTS
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
EP3600233A4 (en) * 2017-03-26 2020-10-21 Stafford, Vivi, Robyn METHOD OF TREATMENT OF SKIN DISEASES OF THE EYELIDS
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018217988A1 (en) * 2017-05-25 2018-11-29 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
JP2020521788A (ja) * 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 免疫アゴニストの投与経路
WO2019011852A1 (en) 2017-07-10 2019-01-17 Innate Pharma POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER
WO2019011855A1 (en) 2017-07-10 2019-01-17 Innate Pharma ANTIBODIES NEUTRALIZING SIGLEC-9
JP7346390B2 (ja) * 2017-09-19 2023-09-19 マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング アゴニスト性ｃｄ４０抗体
MX2020004411A (es) * 2017-11-03 2020-08-06 Novartis Ag Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
CA3083363A1 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
MX2020010722A (es) * 2018-04-13 2020-11-06 Novartis Ag Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
WO2019229699A1 (en) 2018-05-31 2019-12-05 Novartis Ag Hepatitis b antibodies
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EA202092518A1 (ru) 2018-06-18 2021-08-23 Иннейт Фарма Композиции и способы лечения рака
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
US20220025056A1 (en) 2018-12-26 2022-01-27 Innate Pharma Leucocyte immunoglobulin-like receptor neutralizing antibodies
TW202033558A (zh) * 2019-01-11 2020-09-16 瑞士商諾華公司 化膿性汗腺炎治療中使用的抗cd40抗體
CA3136698A1 (en) 2019-04-23 2020-10-29 Innate Pharma Cd73 blocking antibodies
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20220195061A1 (en) 2019-05-08 2022-06-23 Novartis Ag Anti-cd40 antibodies for use in treatment of tidm and insulitis
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
BR112021024938A2 (pt) 2019-06-12 2022-01-25 Novartis Ag Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
KR20220062036A (ko) * 2019-09-11 2022-05-13 노파르티스 아게 환자에서 인간 바이러스 연관된 장애를 방지하는 방법
US20220348632A1 (en) 2019-09-18 2022-11-03 Novartis Ag Nkg2d fusion proteins and uses thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4096625A1 (en) * 2020-01-31 2022-12-07 Sanofi Biotechnology Pulmonary delivery of antibodies
TW202146441A (zh) 2020-02-27 2021-12-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
EP4196500A2 (en) 2020-08-13 2023-06-21 Innate Pharma Cancer treatment methods using anti-cd73 antibodies
JP2023538118A (ja) 2020-08-21 2023-09-06 ノバルティス アーゲー Ｃａｒ発現細胞のインビボ生成のための組成物及び方法
US20230348609A1 (en) * 2020-08-21 2023-11-02 Wuxi Biologics (Shanghai) Co. Ltd. Cd40 agonistic antibody and method of use
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN117295764A (zh) * 2021-06-28 2023-12-26 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及医药用途
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN117858901A (zh) 2021-08-20 2024-04-09 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
CN118234749A (zh) * 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
EP4406971A1 (en) 2021-09-24 2024-07-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-cd40 antibody and use thereof
EP4408537A1 (en) 2021-10-01 2024-08-07 MAB Discovery GmbH Agonistic cd40 antibodies as immune stimulatory agents
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
WO2024056809A1 (en) 2022-09-15 2024-03-21 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US4766A (en) 1846-09-19 Stbaw-cutter
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
KR960704576A (ko) 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)
AU680102B2 (en) 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
AU683158B2 (en) 1994-03-03 1997-10-30 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
CA2292730C (en) 1997-06-13 2008-09-16 Genentech, Inc. Stabilized antibody formulation
ATE272408T1 (de) 1997-06-20 2004-08-15 Biogen Idec Inc Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
EP1224940B2 (de) 1997-09-23 2010-08-11 Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2001034649A2 (en) 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP2004502742A (ja) 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
ATE327004T1 (de) 2000-10-02 2006-06-15 Chiron Corp Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
AU2002243718B2 (en) 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
DE60239931D1 (de) 2001-04-02 2011-06-16 Genentech Inc Kombinationstherapie
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1455812A4 (en) 2001-11-26 2006-03-22 Chiron Corp TREATMENT OF ANTI-CD40 MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
MXPA05008409A (es) 2003-02-10 2005-10-05 Elan Pharm Inc Formulacion de inmunoglobulina y metodo para la preparacion de la misma.
ATE474598T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
DE602004028037D1 (de) 2003-11-04 2010-08-19 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
EP1684805B8 (en) 2003-11-04 2010-08-25 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
JP2008509080A (ja) 2004-04-27 2008-03-27 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006247134B2 (en) 2005-05-18 2012-05-10 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
CN101351478A (zh) 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
CA2633602A1 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
MX2008015541A (es) * 2006-06-06 2008-12-18 Genentech Inc Anticuerpos anti-dll4 y metodos que los usan.
MX2009010620A (es) * 2007-04-02 2009-11-25 Genentech Inc Marcadores biologicos predictivos de respuesta de artritis reumatoide a antagonistas de celula-b.
PT2550972T (pt) * 2007-04-02 2018-05-02 Genentech Inc Anticorpo agonista de klotho-beta para utilização no tratamento de diabetes mellitus ou resistência à insulina
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
KR20220047668A (ko) * 2008-12-09 2022-04-18 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
ES2829423T3 (es) * 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
SG11201507613QA (en) 2013-03-15 2015-10-29 Synaptive Medical Barbados Inc Intelligent positioning system and methods therefore

Also Published As

Publication number Publication date
EP3502138B1 (en) 2022-01-19
CU20130071A7 (es) 2013-09-27
US20240228640A9 (en) 2024-07-11
PT2640749T (pt) 2017-07-25
JO3266B1 (ar) 2018-09-16
DK3502138T3 (da) 2022-04-19
US20200087409A1 (en) 2020-03-19
EP3502138A1 (en) 2019-06-26
TWI608016B (zh) 2017-12-11
HRP20171084T1 (hr) 2017-10-06
US9828433B2 (en) 2017-11-28
UA112417C2 (uk) 2016-09-12
MY159316A (en) 2016-12-30
DK2640749T3 (en) 2017-07-31
TWI531581B (zh) 2016-05-01
US20180118843A1 (en) 2018-05-03
US8828396B2 (en) 2014-09-09
AU2011331288B2 (en) 2014-09-11
IL225719A (en) 2017-09-28
IL225719A0 (en) 2013-06-27
SI3502138T1 (sl) 2022-05-31
US9221913B2 (en) 2015-12-29
MX2013005477A (es) 2013-06-12
EP2640749B1 (en) 2017-04-19
NZ609549A (en) 2015-05-29
CN105949314B (zh) 2021-04-09
UY33728A (es) 2012-06-29
HUE034203T2 (en) 2018-01-29
TW201623335A (zh) 2016-07-01
AR122999A2 (es) 2022-10-19
RS63094B1 (sr) 2022-04-29
LT3502138T (lt) 2022-04-11
WO2012065950A1 (en) 2012-05-24
US9688768B2 (en) 2017-06-27
CO6801629A2 (es) 2013-11-29
CR20130222A (es) 2013-06-28
KR20130080856A (ko) 2013-07-15
EP4023676A1 (en) 2022-07-06
SI2640749T1 (sl) 2017-07-31
AU2011331288A1 (en) 2013-05-02
AR083847A1 (es) 2013-03-27
CU24057B1 (es) 2014-12-26
ES2633817T3 (es) 2017-09-25
EA026133B1 (ru) 2017-03-31
US20120121585A1 (en) 2012-05-17
CN105949314A (zh) 2016-09-21
US20140341898A1 (en) 2014-11-20
US20220204635A1 (en) 2022-06-30
CA2815921C (en) 2021-07-06
MX336633B (es) 2016-01-26
CN103209996A (zh) 2013-07-17
CY1119097T1 (el) 2018-01-10
BR112013011644B1 (pt) 2022-02-22
JP5782132B2 (ja) 2015-09-24
US20160152721A1 (en) 2016-06-02
EP2640749A1 (en) 2013-09-25
MA34654B1 (fr) 2013-11-02
SG189928A1 (en) 2013-06-28
US20240132606A1 (en) 2024-04-25
EP3502138B9 (en) 2022-03-09
CL2013001124A1 (es) 2014-07-04
JP2014500720A (ja) 2014-01-16
PE20140979A1 (es) 2014-08-09
PL3502138T3 (pl) 2022-05-02
PT3502138T (pt) 2022-04-06
HUE058015T2 (hu) 2022-06-28
CN103209996B (zh) 2016-07-20
UY39292A (es) 2021-07-30
CA2815921A1 (en) 2012-05-24
US20170267772A1 (en) 2017-09-21
ZA201302532B (en) 2014-09-25
LT2640749T (lt) 2017-07-10
PL2640749T3 (pl) 2017-09-29
EA201390725A1 (ru) 2013-09-30
US10323096B2 (en) 2019-06-18
EP3222636A1 (en) 2017-09-27
TW201305208A (zh) 2013-02-01
GT201300128A (es) 2015-06-02
US11124578B2 (en) 2021-09-21
KR101632775B1 (ko) 2016-06-22
ES2911460T3 (es) 2022-05-19
BR112013011644A2 (pt) 2016-08-02
HRP20220413T1 (hr) 2022-05-27

Similar Documents

Publication Publication Date Title
IL225719A0 (en) Silenced fc variants of antibodies against 40cd
HK1245284A1 (zh) 抗cd38抗體
AP4082A (en) Anti-cd40 antibodies
EP2658970A4 (en) EXPRESS HUMANIZATION OF ANTIBODIES
IL222222A0 (en) Antibodies against csf-1r
PL2636736T3 (pl) Nowe przeciwciało anty-dr5
HK1199040A1 (en) Use of antibody